2. Academic Validation
  3. Discovery of potent CRTh2 (DP2) receptor antagonists

Discovery of potent CRTh2 (DP2) receptor antagonists

  • Bioorg Med Chem Lett. 2006 Aug 15;16(16):4287-90. doi: 10.1016/j.bmcl.2006.05.062.
Timothy N Birkinshaw 1,  Simon J Teague,  Claire Beech,  Roger V Bonnert,  Stephen Hill,  Anil Patel,  Sara Reakes,  Hitesh Sanganee,  Iain G Dougall,  Tim T Phillips,  Sylvia Salter,  Jerzy Schmidt,  Elizabeth C Arrowsmith,  Juan J Carrillo,  Fiona M Bell,  Stuart W Paine,  Richard Weaver
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Loughborough, UK. [email protected]
PMID: 16753296 DOI: 10.1016/j.bmcl.2006.05.062
Abstract

Starting with the weak agonist indomethacin, a series of potent, selective CRTh2 (DP(2)) antagonists have been discovered as potential treatments for asthma, allergic rhinitis and Other inflammatory diseases.

Figures
Products